Literature DB >> 2570974

Inhibition of soluble CD4 therapy by antibodies to HIV.

L N Callahan, M A Norcross.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2570974     DOI： 10.1016/s0140-6736(89)90790-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Mechanisms for HIV-1 Entry: Current Strategies to Interfere with This Step.

Authors:  Georgia D. Tomaras; Michael L. Greenberg
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

2.  Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.

Authors:  J P Moore; Q J Sattentau; R Wyatt; J Sodroski
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

Review 3.  Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?

Authors:  P J Klasse; Gabriel Ozorowski; Rogier W Sanders; John P Moore
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

4.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors:  E S Daar; X L Li; T Moudgil; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Enzyme-linked immunoassay for human immunodeficiency virus type 1 envelope glycoprotein 120.

Authors:  M Gilbert; J Kirihara; J Mills
Journal:  J Clin Microbiol       Date:  1991-01       Impact factor: 5.948
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.